Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Technology Officer

Chief Scientific Officer

Chief Executive Officer

Chief Medical Officer

Chief Financial Officer

See Remarks

Chief Business Officer

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients....

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-11-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Technology Officer
2023-11-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2023-11-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2023-11-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-11-28	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-11-26	Premium	acquired	Premium	Premium	Premium	Chief Technology Officer
2023-11-26	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-11-26	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-11-26	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-11-26	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-12-09	Premium	bought	Premium	Premium	Premium	-
2022-12-09	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-12-09	Premium	bought	Premium	Premium	Premium	-
2022-12-09	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-12-09	Premium	bought	Premium	Premium	Premium	Chief Technology Officer
2022-12-08	Premium	bought	Premium	Premium	Premium	Chief Technology Officer
2022-12-08	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2022-12-08	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-12-08	Premium	bought	Premium	Premium	Premium	-
2022-12-08	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-12-08	Premium	bought	Premium	Premium	Premium	-
2022-11-28	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-11-28	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer

CADL - Candel Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CADL